<prompt> Lutetium dotatate was approved by FDA in 2018 forTBNeuroendocrine tumoursCrohns diseasePeptic ulcer  <response>: Lutetium Lu 177 dotatate a radiolabeled somatostatin analogue, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumours in adults. 